The rapid quantification of therapeutic monoclonal antibodies
(mAbs)
is of great significance to their pharmacokinetics/pharmacodynamics
(PK/PD) research and the personalized medication for disease treatment.
Taking advantage of the direct decoration of tens of redox tags to
the target of interest, we illustrate herein an amplification-free
ratiometric electrochemical aptasensor for the point-of-care (POC)
detection of trace amounts of therapeutic mAbs. The POC detection
of therapeutic mAbs involved the use of the methylene blue (MB)-conjugated
aptamer as the affinity element and the decoration of therapeutic
mAbs with ferrocene (Fc) tags via the boronate crosslinking, in which
the MB-derived peak current was used as the reference signal, and
the peak current of the Fc tag was used as the output signal. As each
therapeutic mAb carries tens of diol sites for the site-specific decoration
of the Fc output tags, the boronate crosslinking enabled the amplification-free
detection, which is cost-effective and quite simple in operation.
In the presence of bevacizumab (BevMab) as the target, the resulting
ratiometric signal (i.e., the I
Fc/I
MB value) exhibited a good linear response over
the range of 0.025–2.5 μg/mL, and the limit of detection
(LOD) of the electrochemical aptasensor was 6.5 ng/mL. Results indicated
that the aptamer-based affinity recognition endowed the detection
of therapeutic mAbs with high selectivity, while the ratiometric readout
exhibited satisfactory reproducibility and robustness. Moreover, the
ratiometric electrochemical aptasensor is applicable to the detection
of therapeutic mAbs in serum samples. Taking together, the amplification-free
ratiometric electrochemical aptasensor holds great promise in the
POC detection of therapeutic mAbs.